An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

Sponsor
Replimune, Inc.
Study ID
NCT06590480
Status
No Longer Available

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RP1 — BIOLOGICAL
    Genetically modified Herpes Simplex Type 1 Virus
  • Nivolumab — BIOLOGICAL
    Anti-PD-1 Monoclonal Antibody

Study Details

The purpose of this EAP is to provide expanded access (i.e., before marketing authorization) to vusolimogene oderparepvec (VO; herein referred to as VO) plus standard-of-care (SOC), nivolumab, for eligible patients diagnosed with advanced melanoma, who, in their treating physician's opinion, could benefit from this treatment.

Key Dates

First listed
Sep 19, 2024
Status verified
Dec 2025

Related Studies